Titlebook: Topics in Extrinsic Geometry of Codimension-One Foliations; Vladimir Rovenski,Pawe? Walczak Book 2011 Vladimir Rovenski, Pawe? Walczak 201

傷害

書目名稱Topics in Extrinsic Geometry of Codimension-One Foliations影響因子(影響力)




書目名稱Topics in Extrinsic Geometry of Codimension-One Foliations影響因子(影響力)學(xué)科排名




書目名稱Topics in Extrinsic Geometry of Codimension-One Foliations網(wǎng)絡(luò)公開度




書目名稱Topics in Extrinsic Geometry of Codimension-One Foliations網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Topics in Extrinsic Geometry of Codimension-One Foliations被引頻次




書目名稱Topics in Extrinsic Geometry of Codimension-One Foliations被引頻次學(xué)科排名




書目名稱Topics in Extrinsic Geometry of Codimension-One Foliations年度引用




書目名稱Topics in Extrinsic Geometry of Codimension-One Foliations年度引用學(xué)科排名




書目名稱Topics in Extrinsic Geometry of Codimension-One Foliations讀者反饋




書目名稱Topics in Extrinsic Geometry of Codimension-One Foliations讀者反饋學(xué)科排名

Genteel

? Preclinical and clinical researchers now have the opportunity to confirm their hypotheses and the pharmaceutical industry may be able to develop really novel classes of therape978-3-642-44547-7978-3-642-25761-2Series ISSN 0171-2004 Series E-ISSN 1865-0325

爆炸

2191-8198 es of foliations. To develop EGF, one needs .Variational Formulae., revealed in chapter 2, which expresses a change in different extrinsic geometric quantities of a fixed foliation under leaf-wise variation of 978-1-4419-9907-8978-1-4419-9908-5Series ISSN 2191-8198 Series E-ISSN 2191-8201

有權(quán)

BLINK

Book 2011F) on foliated manifolds, which may be a tool for prescribing extrinsic geometric properties of foliations. To develop EGF, one needs .Variational Formulae., revealed in chapter 2, which expresses a change in different extrinsic geometric quantities of a fixed foliation under leaf-wise variation of

令人發(fā)膩

Vladimir Rovenski,Pawe? Walczakacceptance and clinical use; pinhole IOLs are also available to improve pseudoaccommodation and to help patients with irregular corneas; supplementary IOLs are challenging the very concept of IOL selection and will be more and more accepted in the near future.

Uncultured

Vladimir Rovenski,Pawe? Walczakthese impressive advances no change in survival expectancy of patients with osteosarcoma during the past 40 years has occurred. There have been no new chemotherapeutic agents effective in addressing disease that is resistant to current agents; the few that have been introduced await further study to

Incise

meritorious

GLADE

Vladimir Rovenski,Pawe? Walczak century. The first agents that held promise were doxorubicin and high-dose methotrexate with leucovorin (citrovorin factor) in the mid-1970s. Since then, other agents that can eliminate or cause regression of tumor have been discovered: cis-diamminedichloroplatinum II (cisplatin) and the oxazaphosp